Kathleen Goin, the Chief Operating Officer of Palvella Therapeutics, Inc. (NASDAQ: PVLA), completed the disposition of 4,302 shares on June 17, 2026. The total value of the sale was recorded at approximately $476,372, with individual share prices ranging between $110.26 and $112.23. This transaction was facilitated through a Rule 10b5-1 trading plan, which was formally adopted on August 19, 2025. The plan was established during an open trading window when Goin was not in possession of material non-public information, adhering to the Issuer’s Insider Trading Policy.
Preceding the sale, Goin acquired 4,302 shares of common stock through the exercise of fully vested stock options. The acquisition cost ranged from $7.14 to $9.08 per share, resulting in a total value of $34,883. Following the sale, Goin holds zero shares of Palvella Therapeutics common stock directly.
The stock has demonstrated significant volatility, climbing to $118.84, reflecting a 413% return over the past year. According to InvestingPro analysis, the stock currently appears overvalued relative to its Fair Value. The platform offers 12 additional ProTips for PVLA, along with comprehensive financial health metrics for deeper analysis.
In corporate developments, Palvella Therapeutics Inc. has made significant strides in its development of QTORIN rapamycin for treating microcystic lymphatic malformations. The company announced that the U.S. Food and Drug Administration granted a rolling review for its New Drug Application, allowing the FDA to evaluate completed sections of the application before the full submission is complete. Palvella remains on track to finish the NDA submission in the second half of 2026. Additionally, Palvella has completed a pre-NDA meeting with the FDA, discussing nonclinical, clinical pharmacology, and clinical information for the planned NDA.
In corporate governance, Palvella’s shareholders approved an amendment to the 2024 Equity Incentive Plan, increasing the number of shares authorized for issuance by 750,000. This amendment was previously approved by the board and became effective immediately following shareholder approval. Furthermore, ResVita Bio appointed John D. Doux, a board-certified dermatologist and analyst, to its board of directors. Doux also serves as a board director for Palvella Therapeutics.